These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36367870)

  • 21. A Needs Assessment of Persons With Sickle Cell Disease in a Major Medical Center in North Carolina.
    Masese RV; Crego N; Douglas C; Rains G; Bonnabeau E; DeMartino T; Shah N; Tanabe P
    N C Med J; 2021; 82(5):312-320. PubMed ID: 34544765
    [No Abstract]   [Full Text] [Related]  

  • 22. Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry.
    Glassberg JA; Linton EA; Burson K; Hendershot T; Telfair J; Kanter J; Gordeuk VR; King AA; Melvin CL; Shah N; Hankins JS; Epié AY; Richardson LD;
    Orphanet J Rare Dis; 2020 Jul; 15(1):178. PubMed ID: 32635939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation science research for the scale-up of evidence-based interventions for sickle cell disease in africa: a commentary.
    Gyamfi J; Ojo T; Iwelunmor J; Ogedegbe G; Ryan N; Diawara A; Nnodu O; Wonkam A; Royal C; Peprah E
    Global Health; 2021 Feb; 17(1):20. PubMed ID: 33596947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017.
    Su ZT; Segal JB; Lanzkron S; Ogunsile FJ
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1246-1250. PubMed ID: 31328369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
    Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH
    Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.
    Hodges JR; Phillips SM; Norell S; Nwosu C; Khan H; Luo L; Badawy SM; King A; Tanabe P; Treadwell M; Rojas Smith L; Calhoun C; Hankins JS; Porter J
    Blood Adv; 2020 Sep; 4(18):4463-4473. PubMed ID: 32941646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia.
    Albohassan H; Ammen M; Alomran AA; Bu Shehab H; Al Sakkak H; Al Bohassan A
    Cureus; 2022 Nov; 14(11):e31527. PubMed ID: 36540486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability.
    Ryan N; Dike L; Ojo T; Vieira D; Nnodu O; Gyamfi J; Peprah E
    BMJ Open; 2020 Nov; 10(11):e038685. PubMed ID: 33168553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.
    Hankins JS; Estepp JH; Hodges JR; Villavicencio MA; Robison LL; Weiss MJ; Kang G; Schreiber JE; Porter JS; Kaste SC; Saving KL; Bryant PC; Deyo JE; Nottage KA; King AA; Brandow AM; Lebensburger JD; Adesina O; Chou ST; Zemel BS; Smeltzer MP; Wang WC; Gurney JG
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27228. PubMed ID: 29797644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Nevitt SJ; Jones AP; Howard J
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translating sickle cell guidelines into practice for primary care providers with Project ECHO.
    Shook LM; Farrell CB; Kalinyak KA; Nelson SC; Hardesty BM; Rampersad AG; Saving KL; Whitten-Shurney WJ; Panepinto JA; Ware RE; Crosby LE
    Med Educ Online; 2016; 21():33616. PubMed ID: 27887664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
    Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
    JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
    Lanzkron S; Haywood C; Hassell KL; Rand C
    J Natl Med Assoc; 2008 Aug; 100(8):968-73. PubMed ID: 18717150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS), a focus group and decision support tool development project.
    Tanabe P; Reddin C; Thornton VL; Todd KH; Wun T; Lyons JS
    Acad Emerg Med; 2010 Aug; 17(8):848-58. PubMed ID: 20670322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department.
    Linton EA; Goodin DA; Hankins JS; Kanter J; Preiss L; Simon J; Souffront K; Tanabe P; Gibson R; Hsu LL; King A; Richardsona LD; Glassberg JA;
    Ann Emerg Med; 2020 Sep; 76(3S):S64-S72. PubMed ID: 32928465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium.
    Knisely MR; Pugh N; Kroner B; Masese R; Gordeuk V; King AA; Smith SM; Gurney JG; Adams R; Wun T; Snyder A; Glassberg J; Shah N; Treadwell M;
    Am J Hematol; 2020 Sep; 95(9):1066-1074. PubMed ID: 32449965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis.
    Núñez RM; Figueroa CAP; García-Perdomo HA
    J Child Health Care; 2020 Mar; 24(1):64-77. PubMed ID: 30606035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease.
    Hankins JS; Potter MB; Fernandez ME; Melvin C; DiMartino L; Jacobs SR; Bosworth HB; King AA; Simon J; Glassberg JA; Kutlar A; Gordeuk VR; Shah N; Baumann AA; Klesges LM;
    Front Health Serv; 2022; 2():1024541. PubMed ID: 36925803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Kassim AA; DeBaun MR
    Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric to Adult Transition in Sickle Cell Disease: Survey Results from Young Adult Patients.
    Travis K; Wood A; Yeh P; Allahabadi S; Chien LC; Curtis S; Hammond A; Kohn J; Ogugbuaja C; Rees M; Shumway J; Sheehan V
    Acta Haematol; 2020; 143(2):163-175. PubMed ID: 31307033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.